Four-Year Teriparatide Followed by Denosumab vs. Continuous Denosumab in Glucocorticoid-Induced Osteoporosis Patients With Prior Bisphosphonate Treatment

OBJECTIVES: In our previous 24-month study, we observed that teriparatide had some advantages over denosumab for bone mineral density (BMD) in glucocorticoid-induced osteoporosis (GIO) patients with prior bisphosphonate treatment. We conducted this extension study to investigate whether the advantag...

Descripción completa

Detalles Bibliográficos
Autores principales: Hirooka, Yasuaki, Nozaki, Yuji, Okuda, Saki, Sugiyama, Masafumi, Kinoshita, Koji, Funauchi, Masanori, Matsumura, Itaru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8503555/
https://www.ncbi.nlm.nih.gov/pubmed/34646240
http://dx.doi.org/10.3389/fendo.2021.753185

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8503555/
https://www.ncbi.nlm.nih.gov/pubmed/34646240
http://dx.doi.org/10.3389/fendo.2021.753185

Ejemplares similares